Curious about the potential of #AI in unlocking the potential of #precisionmedicine? Check out Andre Esteva, PhD's insights on why scaling genomic testing has been difficult and how ArteraAI could pave the way forward. 🧠🔬 Read more here: medium.com/@artera/unlock…

artera.ai/for-patients is your resource for navigating #cancertreatment with confidence. Discover how the #ArteraAI Prostate Test can help mitigate uncertainty around treatment choices, by providing personalized results for shared decision-making through the use of #AI.

Congratulations to our very own Trevor J. Royce MD MPH FASCO and the rest of the 2024 #FASCO recipients! We know this is a huge accomplishment and we're excited to be working with you all to continue advancing medicine and cancer care. heyor.ca/Mw3xQ0

We're thrilled to share that we have achieved #capaccreditation! This recognition highlights our commitment to high quality standards, ensuring the best practices in everything we do. Thank you to our dedicated team for their hard work and dedication to excellence.

With 20 years of medical experience, Artera's Tim Showalter has had countless conversations with patients that have refined his approach to care. In a piece with Psychology Today, he shares some of the impactful discussions & how they've shaped his practice: bit.ly/3WogLZh

ICYMI: Artera's own Tim Showalter was joined by pathologist Adam Cole in an educational webinar sharing how the #ArteraAI Prostate Test works, how it can benefit patients with localized #prostatecancer, & how to start ordering the test. Learn more: heyor.ca/LO2ZFD

Get to know #ArteraAI's Wayne Lai, Sr. Designer & August Employee of the Month! Wayne is recognized for his innovative designs and ability to always deliver on tight deadlines. Congratulations! 👏 We're proud to have you on our team. #prostatecancer #AI #precisionmedicine

Artera is thrilled to announce the expansion of the #ArteraAI Prostate Test to inform active surveillance decisions for lower risk #prostatecancer patients, including distribution through PathNetLab's extensive network of 200+ clinics across 27 states: heyor.ca/0G4NDc

Looking to learn more about the #ArteraAI Prostate Test? Join Drs. Trevor J. Royce MD MPH FASCO, Tim Kegelman, MD, PhD and zach horne on 8/26 to get all the details about how the test works and how it can benefit patients with localized #prostatecancer. Register now! heyor.ca/q4urIC

For lower risk patients, choosing between active treatment or #activesurveillance is not an easy decision. Take a tour of Artera's sample test report and its #prognostic results to see how it can help clinicians and patients decide if active surveillance is a suitable option:

Today's #DOTW features the ArteraAI Prostate Test, which analyzes biopsy images and clinical data to prognosticate outcomes, guide active surveillance suitability, and predict hormone therapy benefit. It's the first AI test included in NCCN Guidelines®. artera.ai/for-clinicians

At #ArteraAI, we love knowledgeable and empowered patient advocates! Big thanks to Howard Wolinsky and his fantastic write up in Medscape, covering our recent news of new insights in the #ArteraAI Prostate Test to help inform #activesurveillance decisions. heyor.ca/0G4NDci

The #ArteraAI Prostate Test can help mitigate uncertainty around treatment choices. As the first-ever predictive test for localized #prostatecancer, the ArteraAI #ProstateTest can provide personalized results for shared decision-making. 🤝 ➡️ Learn more: artera.ai

Want to hear from current ArteraAI Prostate Test users Drs. Tim Kegelman, MD, PhD and zach horne on how to utilize the report to inform clinical decision making? Register now for our webinar on 8/26 to get all your questions answered. heyor.ca/q4urIC

What is the future for #activesurveillance? Artera's own Mia Li-Burton & Meghan Tierney join the Active Surveillance Patients International (ASPI) panel on August 24th at noon ET to discuss how the #ArteraAI Prostate Test can help with active surveillance decision making. Register now: heyor.ca/y4eiqJ

ArteraAI benefits both clinicians & patients! 🤝 Our MMAI #biomarker test leverages the power of AI, predicting therapeutic benefit from hormone therapy and outperforming standard prognostic tools for patients with localized #prostatecancer: bit.ly/3FP86pB

Our latest validation of the #ArteraAI prognostic model for high-risk localized #prostatecancer was recently published in @euplatinum. Special thanks to @drspratticus for leading this important research. heyor.ca/IwKWMn

It's #ProstateCancerAwarenessMonth. While all men are at risk for #prostatecancer, not all have the same mortality rate. Discover how the #ArteraAI Prostate Test can help mitigate uncertainty around treatment choices by providing personalized results: artera.ai/for-patients

In preparation for #ProstateCancer Awareness Month, #ArteraAI is proud to partner with @ZeroCancer and hosting a virtual walk in September. To learn how how to do likewise, please check out: heyor.ca/lDgxr0 Together, we can #ZEROoutprostatecancer. 🤝

ICYMI: The #ArteraAI Prostate Test has expanded to inform #activesurveillance decisions for lower-risk #prostatecancer patients, in a mission to "empower all those delivering cancer care". ➡️ Read more from Urology Times: urologytimes.com/view/arteraai-…